S
Spyre Therapeutics | Aeglea BioTherapeutics
Develops engineered antibodies with extended half-lives to provide high-potency monotherapies and rational combinations for inflammatory bowel disease
About Spyre Therapeutics | Aeglea BioTherapeutics
Spyre Therapeutics (formerly Aeglea BioTherapeutics) is a clinical-stage biotechnology company focused on developing next-generation antibody therapeutics for inflammatory bowel disease (IBD). Following the 2023 acquisition of Spyre Therapeutics by Aeglea and subsequent rebranding, the company transitioned away from its historical emphasis on engineered human enzymes for rare metabolic diseases to a new focus on immunology-driven therapies with potential best-in-class profiles.
Read full description
Spyre is building a diversified pipeline of long-acting antibodies designed to target validated pathways in IBD, including anti-α4β7 and anti-TL1A programs. These candidates aim to improve durability, patient convenience, and combination-therapy potential. The company’s business model centers on the discovery, clinical development, and commercialization of innovative biologics that address large, underserved markets in inflammatory disease.
As a clinical-stage company, Spyre Therapeutics does not yet have approved products, and its operations are primarily funded through venture investment, public equity financing, and partnerships. The company serves a significant unmet need within the gastrointestinal therapeutics market, focusing on more effective and durable treatment options for patients with ulcerative colitis and Crohn’s disease.
The company’s legacy rare-disease enzyme program—pegzilarginase for Arginase 1 Deficiency—has been deprioritized following the strategic shift and is now maintained only as part of historical Aeglea development activities.
At a glance
- Founded
- 2013
- Headquarters
- Waltham, United States
- Listing
- IPO 2016
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A19 investors entered at this stage
Lilly Ventures
Novartis Venture Fund
UT Horizon Fund
KBI Biopharma
Venrock
New Ground Ventures
Wellington Management
Fidelity Investments
RTW Investments
Driehaus Capital Management
Cormorant Asset Management
RA Capital Management
EcoR1 Capital
Commodore Capital
Surveyor Capital
Deep Track Capital
Perceptive Advisors
Fairmount Funds Management- VPVenrock Healthcare Capital Partners
Series B and later17 investors entered at this stage
- AAAffinity Asset Advisors
- NVNew Ground Ventures
- UAUniversity of Texas at Austin
- DCDeep Track Capital
- BCBoxer Capital
- GCGreat Point Capital
- Venrock
- BRBraidwell
- AIAccess Industries
- CCCommodore Capital
- Perceptive Advisors
- RIRTW Investments
- WPWoodline Partners
- FMFairmount Funds Management
- VPVenrock Healthcare Capital Partners
- Cormorant Asset Management
- PCPolar Capital
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Patents
12 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Spyre Therapeutics | Aeglea BioTherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Spyre Therapeutics | Aeglea BioTherapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.